Makoto Otsu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7070357/makoto-otsu-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92 papers	6,076 citations	27 h-index	77 g-index
96 ext. papers	6,909 ext. citations	7.9 avg, IF	4.74 L-index

#	Paper	IF	Citations
92	Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 424-433	6.4	0
91	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption. *Journal of Dental Research*, **2020**, 99, 429-436	8.1	7
90	Simple and Robust Differentiation of Human Pluripotent Stem Cells toward Chondrocytes by Two Small-Molecule Compounds. *Stem Cell Reports*, **2019**, 13, 530-544	8	15
89	Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34 cells using the auto-erasable Sendai virus vector. *Stem Cell Research and Therapy*, **2019**, 10, 185	8.3	17
88	Generation of three induced pluripotent stem cell lines from postmortem tissue derived following sudden death of a young patient with STXBP1 mutation. *Stem Cell Research*, **2019**, 39, 101485	1.6	3
87	Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity. *Stem Cell Reports*, **2018**, 11, 380-394	8	16
86	Designing Motif-Engineered Receptors To Elucidate Signaling Molecules Important for Proliferation of Hematopoietic Stem Cells. *ACS Synthetic Biology*, **2018**, 7, 1709-1714	5.7	7
85	Enhanced Selective Inhibition of KRAS Mutant Hematopoietic Progenitor Cell Expansion By MEK and Bcl-2 Inhibition. *Blood*, **2018**, 132, 1278-1278	2.2	
84	A Refined Culture System for Human Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Organoids. *Stem Cell Reports*, **2018**, 10, 314-328	8	56
83	Dissection of Signaling Events Downstream of the c-Mpl Receptor in Murine Hematopoietic Stem Cells Via Motif-Engineered Chimeric Receptors. *Stem Cell Reviews and Reports*, **2018**, 14, 101-109	6.4	4
82	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. *Scientific Reports*, **2018**, 8, 15855	4.9	15
81	An All-Recombinant Protein-Based Culture System Specifically Identifies Hematopoietic Stem Cell Maintenance Factors. *Stem Cell Reports*, **2017**, 8, 500-508	8	21
80	Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of Sjögren's Syndrome. *Stem Cell Reports*, **2017**, 8, 1155-1163	8	9
79	Reciprocal Inflammatory Signaling Between Intestinal Epithelial Cells and Adipocytes in the Absence of Immune Cells. *EBioMedicine*, **2017**, 23, 34-45	8.8	26
78	Pre-Transplantation Blockade of TNF-Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells. *Stem Cells*, **2017**, 35, 989-1002	5.8	15
77	Conditional rod photoreceptor ablation reveals Sall1 as a microglial marker and regulator of microglial morphology in the retina. *Glia*, **2016**, 64, 2005-24	9	32
76	Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene Therapy. *Human Gene Therapy Methods*, **2016**, 27, 197-208	4.9	11

75	Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II. *Molecular Genetics and Metabolism*, **2016**, 119, 232-238	3.7	12
74	Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. *Journal of Experimental Medicine*, **2016**, 213, 1865-80	16.6	5
73	Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. *Journal of Clinical Immunology*, **2015**, 35, 384-98	5.7	18
72	Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease. *International Journal of Hematology*, **2015**, 102, 111-20	2.3	1
71	Effects of enzyme replacement therapy on immune function in ADA deficiency patient. *Clinical Immunology*, **2015**, 161, 391-3	9	8
70	Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II. *Journal of Inherited Metabolic Disease*, **2015**, 38, 333-40	5.4	5
69	An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. *Molecular Therapy - Methods and Clinical Development*, **2015**, 2, 15046	6.4	6
68	Characterization of mesenchymal progenitor cells in the crown and root pulp of primary teeth. *Biomedical Research*, **2015**, 36, 31-45	1.5	15
67	Perspectives on stem cell gene therapy for genetic disorders. *ISBT Science Series*, **2015**, 10, 231-234	1.1	1
66	Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. *PLoS ONE*, **2015**, 10, e0120841	3.7	17
65	Reactive oxygen species in hematopoietic stem cells affect culture outcomes under inflammatory conditions. *Open Journal of Hematology*, **2015**, 6, 1		1
64	Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution. *Blood*, **2015**, 126, 3071-3071	2.2	
63	The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-□glucosidase in Pompe□s iPSCs. *Molecular Genetics and Metabolism*, **2014**, 112, 44-8	3.7	23
62	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. *Experimental Hematology*, **2014**, 42, 816-25	3.1	15
61	Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. *Blood*, **2014**, 123, 3932-42	2.2	12
60	Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. *Leukemia*, **2014**, 28, 1844-50	10.7	35
59	Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons. *Nature Communications*, **2014**, 5, 5514	17.4	52
58	DNA Methylation Is Involved in the Expression of miR-142-3p in Fibroblasts and Induced Pluripotent Stem Cells. *Stem Cells International*, **2014**, 2014, 101349	5	5

57	Stage-specific roles for CXCR4 signaling in murine hematopoietic stem/progenitor cells in the process of bone marrow repopulation. *Stem Cells*, **2014**, 32, 1929-42	5.8	29
56	Nuclear receptor gene alteration in human induced pluripotent stem cells with hepatic differentiation propensity. *Hepatology Research*, **2014**, 44, E408-19	5.1	9
55	A New Strategy to Overcome the Cell Dose Barrier to Umbilical Cord Blood Transplants: A Proof of Early Hematopoietic Reconstitution By Combined Multiple Units of Allogeneic Stem/Progenitor Cells. *Blood*, **2014**, 124, 3810-3810	2.2	
54	Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nature Genetics*, **2013**, 45, 1232-7	36.3	258
53	Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. *Cell Metabolism*, **2013**, 18, 759-766	24.6	145
52	Immortalization of erythroblasts by c-MYC and BCL-XL enables large-scale erythrocyte production from human pluripotent stem cells. *Stem Cell Reports*, **2013**, 1, 499-508	8	56
51	Generation of transgenic mouse line expressing Kusabira Orange throughout body, including erythrocytes, by random segregation of provirus method. *Biochemical and Biophysical Research Communications*, **2013**, 435, 586-91	3.4	19
50	Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells. *Journal of Biotechnology*, **2013**, 168, 659-65	3.7	3
49	ACTN1 mutations cause congenital macrothrombocytopenia. *American Journal of Human Genetics*, **2013**, 92, 431-8	11	154
48	Stem cell therapy: an exercise in patience and prudence. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2013**, 368, 20110334	5.8	22
47	Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. *Molecular Therapy*, **2013**, 21, 1424-31	11.7	148
46	Generation of Col2a1-EGFP iPS cells for monitoring chondrogenic differentiation. *PLoS ONE*, **2013**, 8, e74137	3.7	17
45	Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. *Journal of Clinical Investigation*, **2013**, 123, 3802-14	15.9	52
44	Profiling of microRNA in human and mouse ES and iPS cells reveals overlapping but distinct microRNA expression patterns. *PLoS ONE*, **2013**, 8, e73532	3.7	23
43	In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. *Blood*, **2012**, 119, e45-56	2.2	63
42	In vitro cell subtype-specific transduction of adeno-associated virus in mouse and marmoset retinal explant culture. *Biochimie*, **2012**, 94, 2716-22	4.6	12
41	Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. *Blood*, **2012**, 119, 6234-42	2.2	123
40	Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. *Current Gene Therapy*, **2012**, 12, 410-6	4.3	75

39	Biological Analysis of SRSF2 Mutations in Leukemogenesis. *Blood*, **2012**, 120, 1282-1282	2.2	2
38	Growth promotion of genetically modified hematopoietic progenitors using an antibody/c-Mpl chimera. *Cytokine*, **2011**, 55, 402-8	4	19
37	Heterozygous ITGA2B R995W mutation inducing constitutive activation of the IIb3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. *Blood*, **2011**, 117, 5479-84	2.2	69
36	Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature*, **2011**, 478, 64-9	50.4	1415
35	Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. *Journal of Gene Medicine*, **2011**, 13, 262-8	3.5	7
34	Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region. *International Journal of Oncology*, **2011**, 39, 41-9	4.4	2
33	Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia. *Blood*, **2011**, 118, 458-458	2.2	1
32	Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder- and serum-free defined conditions. *PLoS ONE*, **2010**, 5, e14099	3.7	41
31	Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. *Journal of Experimental Medicine*, **2010**, 207, 2817-30	16.6	255
30	Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. *Cell Cycle*, **2010**, 9, 1051-6	4.7	11
29	Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. *Clinical Cancer Research*, **2010**, 16, 3825-31	12.9	28
28	Reprogramming adult hematopoietic cells. *Current Opinion in Hematology*, **2010**, 17, 271-5	3.3	21
27	Transient activation ofc-MYCexpression is critical for efficient platelet generation from human induced pluripotent stem cells. *Journal of Cell Biology*, **2010**, 191, i11-i11	7.3	1
26	Kinetics and effect of integrin expression on human CD34(+) cells during murine leukemia virus-derived retroviral transduction with recombinant fibronectin for stem cell gene therapy. *Human Gene Therapy*, **2009**, 20, 777-83	4.8	2
25	The actin polymerization regulator WAVE2 is required for early bone marrow repopulation by hematopoietic stem cells. *Stem Cells*, **2009**, 27, 1120-9	5.8	15
24	Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. *Nature*, **2009**, 460, 904-8	50.4	338
23	CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. *Nature Medicine*, **2009**, 15, 914-20	50.5	1567
22	T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera. *Cytokine*, **2009**, 46, 127-36	4	28

21	Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. *Blood*, **2009**, 114, 1764-7	2.2	44
20	Unique Gain-of-Function of Mutated c-CBL Tumor Suppresor in Myeloid Neoplasms.. *Blood*, **2009**, 114, 2970-2970	2.2	
19	Detection of a novel silent deletion, a missense mutation and a nonsense mutation in TCOF1. *Pediatrics International*, **2008**, 50, 806-9	1.2	5
18	A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells. *Journal of Gene Medicine*, **2008**, 10, 965-71	3.5	18
17	Stable transgene expression in mice generated from retrovirally transduced embryonic stem cells. *Molecular Therapy*, **2007**, 15, 560-5	11.7	9
16	Stem Cell Gene Therapy for ADA-Deficiency without Myelopreparative Conditioning **2007**, 1-18		0
15	Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. *Molecular Therapy*, **2006**, 13, 301-9	11.7	33
14	Gene therapy: X-SCID transgene leukaemogenicity. *Nature*, **2006**, 443, E5-6; discussion E6-7	50.4	129
13	Molecular analysis of non-syndromic preaxial polydactyly: preaxial polydactyly type-IV and preaxial polydactyly type-I. *Clinical Genetics*, **2005**, 67, 429-33	4	21
12	A case of C3 deficiency with a novel homozygous two-base deletion in the C3 gene. *American Journal of Medical Genetics, Part A*, **2005**, 138, 399-400	2.5	6
11	A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. *Journal of Virological Methods*, **2004**, 118, 61-7	2.6	6
10	Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy. *Human Gene Therapy*, **2002**, 13, 425-32	4.8	10
9	Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells. *Blood*, **2002**, 100, 1248-56	2.2	19
8	Gene therapy in infants with severe combined immunodeficiency. *BioDrugs*, **2002**, 16, 229-39	7.9	12
7	Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice. *Blood*, **2001**, 97, 1618-24	2.2	21
6	Gene therapy for primary immune deficiencies. *Current Opinion in Allergy and Clinical Immunology*, **2001**, 1, 497-501	3.3	2
5	Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 8697-702	11.5	125
4	Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model. *Molecular Therapy*, **2001**, 3, 565-73	11.7	20

3	Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. *Molecular Therapy*, **2000**, 1, 145-53	11.7	55
2	In vivo competitive studies between normal and common gamma chain-defective bone marrow cells: implications for gene therapy. *Human Gene Therapy*, **2000**, 11, 2051-6	4.8	14
1	Successful intravenous immunoglobulin therapy for recurrent pneumococcal otitis media in young children. *European Journal of Pediatrics*, **1994**, 153, 174-8	4.1	11